HYUNDAI BIOLAND Co.Ltd (052260) fair value: what the stock is really worth
As of Oct 29, 2026: fair value (intrinsic value) of HYUNDAI BIOLAND Co.Ltd stock KRW 5,069, price KRW 4,105, upside +23.5%, quality 58 out of 100. Rating: undervalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with oneYes, for free
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Oct 28, 2026.
How to read this chart
60‑month range 3,225 KRW – 11,341 KRW · fair‑value band 3,411 KRW – 6,727 KRW · the 4,105 KRW price screens below the 5,069 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 1 fiscal year is left out: there the valuation rested on only a fraction of the usual models. As of Oct 28, 2026.
Follow HYUNDAI BIOLAND Co.Ltd in your weekly email
Every Wednesday you see whether HYUNDAI BIOLAND Co.Ltd is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
HYUNDAI BIOLAND Co.,Ltd manufactures and sells raw materials for cosmetics, nutraceuticals, and regenerative medicines.
Show moreShow less
It offers anti-aging, moisturizing, whitening, skin protection, and other cosmetic ingredients; functional food ingredients and general food raw materials; and active pharmaceutical ingredients.
The company was formerly known as SKbioland Co., Ltd. and changed its name to HYUNDAI BIOLAND Co.,Ltd in October 2020. HYUNDAI BIOLAND Co.,Ltd was incorporated in 1995 and is based in Cheongju, South Korea.
Stock analysis
HYUNDAI BIOLAND Co.Ltd (052260) currently trades at 4,105 KRW, while our model-based Fair Value estimate is 5,069 KRW, implying the stock looks roughly 19.0% undervalued today.
Show more
Valuation
Bull case: the Growth DCF group reads highest at a median of 6,275 KRW per share, and 11 of the 26 models we run sit above the 4,105 KRW price.
Bear case: the Dividend Discount group reads lowest at 708.16 KRW, and 15 of the 26 models stay below the price. Data coverage for this calculation is medium.
Scenario range: 3,411 KRW (bear) to 6,727 KRW (bull), the price of 4,105 KRW sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 58/100 (solid quality), in the Consumer Non-Cyclicals sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
HYUNDAI BIOLAND Co.Ltd reported revenue of 131B KRW in FY2025 versus 103B KRW in FY2021, a compound +6.1%/yr. Reported net income was 253M KRW in FY2025.
Key figures
Market cap 123B KRW (≈ $92.2M) Micro · P/S ratio 1.22 · Dividend yield 1.7% · Net margin −9.1% · Return on equity 1,004% · Return on assets (EBIT) 3.8% · Operating margin 9.9% · Revenue (TTM) 103B KRW.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 27 out of 100 (medium confidence).
What moves the price
The share trades about 28% below its 52-week high and 27% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Consumer Non-Cyclicals peers we cover trades at −22% fair-value upside, at 23%, 052260 screens cheaper than that median.
Fair Value models
Bear3,411 KRWFair Value 5,069 KRWBull6,727 KRW
Price 4,105 KRW · Upside +23.5%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.81/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+9.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+9.6%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+8.0%
Start year 2020 (pandemic). Over 10 years: +4.9% a year
Revenue growth 14 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+4.7%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in KRW ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Basis: EBIT basis. Measured in KRW: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
−12.9%
Earnings growth per share plus dividend.
Earnings per share, growth per year−14.6%
Dividend (yield on the price)1.7%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−59.0% vs −36.8%, slowing
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.−19% → 10%
Pace: the 5-year rate starts in 2020 (pandemic)
⚠ Revenue per share shrinking 7.2%/yr over ~7Y (margins eroding too) ⓘStructural-decline marker: revenue PER SHARE has fallen over the last decade (robust median trend, not a single year). Backtested across 2005 to 2017, such businesses trailed the market by about 2.5 percentage points per year. Display only: it does not change the fair value or the quality score.
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
−4.7%
The company could shrink this much every year for the next five years and today's price would still be justified.
What forecasts expect
n/a
No analyst forecast available.
After inflation (South Korea: IMF forecast 2.1% a year to 2030, 2.1% from 2016 to 2025) that is about −6.6% a year for the price.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its sector: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median. (Industry “Personal & Household Products & Services” was too small, so the broader sector is used.)Consumer Staples · 1653 stocks
Beats the sector median on 6/11 measures
A mixed picture versus its sector peers.
Valuation
Quality Score58 · Above median
Fair Value upside+23.5% · Above median
Profitability
Return on assets0.2% · Bottom 25%
Net margin (12 months)−9.1% · Bottom 25%
Operating margin (12 months)9.9% · Above median
Growth and dividend
Revenue growth (quarter YoY)−6.0% · Bottom 25%
Dividend yield (12 months)1.7% · Below median
Valuation Multiplesvs Consumer Staples median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is HYUNDAI BIOLAND Co.Ltd (052260) overvalued or undervalued?
As of Oct 28, 2026, our model estimates a fair value of 5,069 KRW versus a price of 4,105 KRW, about +23% upside (undervalued).
What is the fair value of 052260?
Our model-based fair value for HYUNDAI BIOLAND Co.Ltd is 5,069 KRW (as of Oct 28, 2026), built from audited fundamentals. The current price: 4,105 KRW.
What is the quality score of 052260?
HYUNDAI BIOLAND Co.Ltd has a Quality Score of 58/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for HYUNDAI BIOLAND Co.Ltd (052260)?
Our model-based price target is the fair value of 5,069 KRW (as of Oct 28, 2026) from 26 valuation models. Cautious scenario 3,411 KRW, optimistic scenario 6,727 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the HYUNDAI BIOLAND Co.Ltd stock forecast for 2026?
Our models put fair value at 5,069 KRW, about +23% upside versus a price of 4,105 KRW (undervalued). Cautious scenario 3,411 KRW, optimistic scenario 6,727 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of HYUNDAI BIOLAND Co.Ltd (052260)?
HYUNDAI BIOLAND Co.Ltd reported trailing-twelve-month revenue of about 103B KRW (latest available figure, as of Oct 28, 2026).
Does HYUNDAI BIOLAND Co.Ltd pay a dividend?
HYUNDAI BIOLAND Co.Ltd currently shows a dividend yield of 1.72% relative to its recent price (as of Oct 28, 2026).
What growth is priced into HYUNDAI BIOLAND Co.Ltd (052260)?
For today's price to be fair in a discounted-cash-flow model, HYUNDAI BIOLAND Co.Ltd would have to grow free cash flow by -4.7 % per year for five years (discount rate 12.4 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +8.0 % per year. As of Oct 28, 2026.
What discount rate (WACC) does the fair value of 052260 use?
Our models discount HYUNDAI BIOLAND Co.Ltd at 12.4 %: a base by market capitalisation (micro), damped by beta 0.77, country premium for South Korea. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For HYUNDAI BIOLAND Co.Ltd that is -4.7 % per year a year over ten years, using the same discount rate (12.4 %) and the same formula as our fair value.
How much growth has HYUNDAI BIOLAND Co.Ltd (052260) delivered so far?
Over the past 5 years revenue at HYUNDAI BIOLAND Co.Ltd grew +8.0 % a year. The price currently implies -4.7 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of HYUNDAI BIOLAND Co.Ltd (052260) growing?
The median revenue growth in the sector is +3.2 % a year. That is the yardstick for the growth priced into HYUNDAI BIOLAND Co.Ltd (-4.7 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of HYUNDAI BIOLAND Co.Ltd (052260)?
The free-cash-flow yield on the price is 12.51 %: that much free cash flow HYUNDAI BIOLAND Co.Ltd produces per unit of market value. When it exceeds the discount rate of our models (12.4 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of HYUNDAI BIOLAND Co.Ltd (052260)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For HYUNDAI BIOLAND Co.Ltd it is 5,069 KRW per share (as of Oct 28, 2026), against a price of 4,105 KRW. It is the blended result of 26 valuation models (cash flow, earnings, asset, dividend).
Is HYUNDAI BIOLAND Co.Ltd stock overvalued or undervalued in 2026?
As of Oct 28, 2026, 052260 trades below its calculated fair value: price 4,105 KRW, fair value 5,069 KRW, a gap of about +23% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 052260?
No. The price is what the market pays today (4,105 KRW); the fair value is what the company's own numbers justify (5,069 KRW). For HYUNDAI BIOLAND Co.Ltd the two are 963.99 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is HYUNDAI BIOLAND Co.Ltd worth?
The market values HYUNDAI BIOLAND Co.Ltd at about 123B KRW (market capitalisation, as of Oct 28, 2026). Per share that is 4,105 KRW; our models calculate a fair value of 5,069 KRW per share.
What do the bullish and bearish scenarios say about 052260?
Our models span a range for HYUNDAI BIOLAND Co.Ltd: cautious scenario 3,411 KRW, base 5,069 KRW, optimistic 6,727 KRW per share (as of Oct 28, 2026, price 4,105 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How far is 052260 from its 52-week high?
HYUNDAI BIOLAND Co.Ltd trades at 4,105 KRW, about 28% below its 52-week high of 5,670 KRW and 27% above the low of 3,225 KRW (as of Oct 29, 2026). Distance from the high says nothing about value: that is what the fair value of 5,069 KRW is for.
Which stocks are comparable to HYUNDAI BIOLAND Co.Ltd?
From the same area (Consumer Non-Cyclicals) we also value NeoPharm CO., LTD., Csa Cosmic Co, Auxilia S.A, FB, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is HYUNDAI BIOLAND Co.Ltd stock attractive at the current price?
The data as of Oct 28, 2026: price 4,105 KRW, calculated fair value 5,069 KRW (+23%), Quality Score 58/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 052260 calculated?
We run HYUNDAI BIOLAND Co.Ltd through 26 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 5,069 KRW, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3 % above its aggregate fair value. HYUNDAI BIOLAND Co.Ltd currently trades 19 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of HYUNDAI BIOLAND Co.Ltd (052260)?
The closing price on Oct 29, 2026 was 4,105 KRW. Our model-based fair value is 5,069 KRW, about +23% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with HYUNDAI BIOLAND Co.Ltd right now?
Solid quality (58/100) at a price below fair value, the discount is the argument here, not the business quality. A fairly wide model range (3,411 KRW to 6,727 KRW) leaves room in how you read the outcome.
Key figures of HYUNDAI BIOLAND Co.Ltd
How large is the market capitalisation of HYUNDAI BIOLAND Co.Ltd (052260)?
The market capitalisation of HYUNDAI BIOLAND Co.Ltd is 123B KRW (≈ $92.2M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of HYUNDAI BIOLAND Co.Ltd (052260)?
The price-to-sales ratio of HYUNDAI BIOLAND Co.Ltd is 1.22 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the dividend yield of HYUNDAI BIOLAND Co.Ltd (052260)?
The dividend yield of HYUNDAI BIOLAND Co.Ltd is 1.7%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of HYUNDAI BIOLAND Co.Ltd (052260)?
The net margin of HYUNDAI BIOLAND Co.Ltd is −9.1% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of HYUNDAI BIOLAND Co.Ltd (052260)?
The return on equity (ROE) of HYUNDAI BIOLAND Co.Ltd is 1,004% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of HYUNDAI BIOLAND Co.Ltd (052260)?
On an EBIT basis the return on assets of HYUNDAI BIOLAND Co.Ltd is 3.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of HYUNDAI BIOLAND Co.Ltd (052260)?
The operating margin of HYUNDAI BIOLAND Co.Ltd is 9.9% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at HYUNDAI BIOLAND Co.Ltd (052260)?
Revenue at HYUNDAI BIOLAND Co.Ltd is growing −6.0% versus a year earlier (3y avg +9.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at HYUNDAI BIOLAND Co.Ltd (052260)?
Earnings per share at HYUNDAI BIOLAND Co.Ltd are growing +37.7% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does HYUNDAI BIOLAND Co.Ltd (052260) carry?
The net debt of HYUNDAI BIOLAND Co.Ltd is 13.7B KRW (fiscal year 2024, ≈ 0.9 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch HYUNDAI BIOLAND Co.Ltd in the live analysis
One click puts HYUNDAI BIOLAND Co.Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 28,000+ stock screener.
Some data
Oct 28, 2026